BACKGROUND: Histone deacetylase (HDAC) inhibitors represent a novel class of therapeutic agents with antitumor activity currently in clinical development. In this study, we tested the biological effects of the HDAC inhibitor MS-275 in various pre-clinical prostate cancer models both in'vitro and in vivo. METHODS: In vitro cell proliferation XTT assay and protein expression analysis by Western blot were performed. In vivo tumor growth assessment in subcutaneous, orthotopic, and transgenic mouse models were conducted. RESULTS: MS-275 significantly upregulated histone H3 acetylation and p21 gene expression in human prostate cancer cell lines. MS-275 exerted growth arrest in PC-3 and LNCaP cells, and induced cell death in DU-145 cells. Prostate specific antigen protein levels were increased by MS-275 in LAPC4 cell line. In vivo, MS-275 inhibited the growth of DU-145, LNCaP, and PC-3 in subcutaneous xenografts. MS-275 had also a significant inhibition of PC-3 cells growth in a mouse intratibial model. Molecular analysis showed increased histone acetylation and p21 expression in tumor samples from MS-275-treated mice. In transgenic adenocarcinoma of mouse prostate (TRAMP) mice, long-term treatment of MS-275 slowed the progression of prostate carcinomas with significant reduction in cell proliferation. CONCLUSIONS: Taken together, these data support the clinical testing of MS-275 for the treatment of prostate cancer. (c) 2007 Wiley-Liss, Inc.
BACKGROUND: Histone deacetylase (HDAC) inhibitors represent a novel class of therapeutic agents with antitumor activity currently in clinical development. In this study, we tested the biological effects of the HDAC inhibitor MS-275 in various pre-clinical prostate cancer models both in'vitro and in vivo. METHODS: In vitro cell proliferation XTT assay and protein expression analysis by Western blot were performed. In vivo tumor growth assessment in subcutaneous, orthotopic, and transgenic mouse models were conducted. RESULTS:MS-275 significantly upregulated histone H3 acetylation and p21 gene expression in humanprostate cancer cell lines. MS-275 exerted growth arrest in PC-3 and LNCaP cells, and induced cell death in DU-145 cells. Prostate specific antigen protein levels were increased by MS-275 in LAPC4 cell line. In vivo, MS-275 inhibited the growth of DU-145, LNCaP, and PC-3 in subcutaneous xenografts. MS-275 had also a significant inhibition of PC-3 cells growth in a mouse intratibial model. Molecular analysis showed increased histone acetylation and p21 expression in tumor samples from MS-275-treated mice. In transgenic adenocarcinoma of mouse prostate (TRAMP) mice, long-term treatment of MS-275 slowed the progression of prostate carcinomas with significant reduction in cell proliferation. CONCLUSIONS: Taken together, these data support the clinical testing of MS-275 for the treatment of prostate cancer. (c) 2007 Wiley-Liss, Inc.
Authors: Hao Geng; Brooks L Rademacher; Janet Pittsenbarger; Chung-Ying Huang; Christopher T Harvey; Marie C Lafortune; Anne Myrthue; Mark Garzotto; Peter S Nelson; Tomasz M Beer; David Z Qian Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701
Authors: R Mazzucchelli; M Scarpelli; A Lopez-Beltran; L Cheng; H Bartels; P H Bartels; D S Alberts; R Montironi Journal: Int J Immunopathol Pharmacol Date: 2011 Apr-Jun Impact factor: 3.219
Authors: Thi Lien-Anh Nguyên; Hesham Abdelbary; Meztli Arguello; Caroline Breitbach; Simon Leveille; Jean-Simon Diallo; Amber Yasmeen; Tarek A Bismar; David Kirn; Theresa Falls; Valerie E Snoulten; Barbara C Vanderhyden; Joel Werier; Harold Atkins; Markus J V Vähä-Koskela; David F Stojdl; John C Bell; John Hiscott Journal: Proc Natl Acad Sci U S A Date: 2008-09-24 Impact factor: 11.205
Authors: Deborah Bradley; Dana Rathkopf; Rodney Dunn; Walter M Stadler; Glenn Liu; David C Smith; Roberto Pili; James Zwiebel; Howard Scher; Maha Hussain Journal: Cancer Date: 2009-12-01 Impact factor: 6.860
Authors: David Z Qian; Brooks L S Rademacher; Janet Pittsenbarger; Chung-Ying Huang; Anne Myrthue; Celestia S Higano; Mark Garzotto; Peter S Nelson; Tomasz M Beer Journal: Prostate Date: 2010-03-01 Impact factor: 4.104